SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours
Keyword(s):
Stage Iv
◽
2015 ◽
Vol 10
(1)
◽
pp. 134-142
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8004-8004
◽
Keyword(s):
2019 ◽
Keyword(s):